Stay updated with breaking news from Endogenous Cushing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate ... Strongbridge Biopharma plcMay 12, 2021 GMT ~ Reports KEVEYIS ® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021 KEVEYIS (dichlorphenamide) Revenue Guidance of Approximately $34 Million to $36 Million ~ ~ Awaiting Day 74 Letter from U.S. Food & Drug Administration (FD...